Xilio Therapeutics, Inc.
NASDAQ:XLO
1.15 (USD) • At close December 24, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2.263 | 2.357 | 0 | 2.902 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0.445 | 0.443 | 0.449 | 0.46 | 0.492 | 0.499 | 0.489 | 0.473 | 0.445 | 0.44 | 0.394 | 0.382 | 0.373 | 0.35 | 0 | 0 | 0 | 0 |
| Gross Profit
| 2.263 | 1.912 | -0.443 | 2.453 | -0.46 | -0.492 | -0.499 | -0.489 | -0.473 | -0.445 | -0.44 | -0.394 | -0.382 | -0.373 | -0.35 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 1 | 0.811 | 0 | 0.845 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 10.759 | 11.216 | 10.4 | 11.736 | 11.051 | 13.218 | 16.131 | 14.997 | 13.038 | 16.246 | 14.92 | 11.352 | 10.47 | 17.745 | 11.621 | 17.667 | 11.46 | 9.147 | 5.636 |
| General & Administrative Expenses
| 6.307 | 5.815 | 6.139 | 6.394 | 6.31 | 6.898 | 7.395 | 8.17 | 7.168 | 8.306 | 6.304 | 8.204 | 5.491 | 5.262 | 4.899 | 2.928 | 3.163 | 2.3 | 2.262 |
| Selling & Marketing Expenses
| 0 | -0.445 | -0.443 | 5.939 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 6.307 | 5.37 | 5.696 | 5.945 | 6.31 | 6.898 | 7.395 | 8.17 | 7.168 | 8.306 | 6.304 | 8.204 | 5.491 | 5.262 | 4.899 | 2.928 | 3.163 | 2.3 | 2.262 |
| Other Expenses
| -0.041 | 0.779 | 0.284 | -2.254 | 0.613 | 0.761 | 0.88 | 0.701 | 0.416 | -0.061 | -0.129 | -0.145 | -0.29 | -0.174 | -0.147 | -0.177 | -0.196 | 0 | 0 |
| Operating Expenses
| 17.025 | 16.586 | 16.096 | 17.681 | 17.361 | 20.116 | 23.526 | 23.167 | 20.206 | 24.552 | 21.224 | 19.556 | 15.961 | 23.007 | 16.52 | 20.595 | 14.623 | 11.51 | 8.118 |
| Operating Income
| -14.762 | -14.674 | -16.539 | -18.13 | -17.361 | -20.116 | -23.526 | -23.167 | -20.206 | -24.552 | -21.224 | -19.556 | -15.961 | -23.007 | -16.52 | -20.595 | -14.623 | -11.447 | -7.898 |
| Operating Income Ratio
| -6.523 | -6.226 | 0 | -6.247 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0.742 | 0.779 | -0.664 | 0.475 | 0.613 | 0.761 | 0.88 | 0.701 | 0.416 | -0.061 | -0.129 | -0.145 | -0.29 | -0.174 | -0.147 | -0.177 | -0.196 | -0.063 | -0.22 |
| Income Before Tax
| -14.02 | -13.925 | -17.203 | -17.655 | -16.748 | -19.355 | -22.646 | -22.466 | -19.79 | -24.613 | -21.353 | -19.701 | -16.251 | -23.181 | -16.667 | -20.772 | -14.819 | -11.51 | -8.118 |
| Income Before Tax Ratio
| -6.195 | -5.908 | 0 | -6.084 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | 0 | 1.379 | 0.5 | 0.37 | -1.379 | -0.701 | -0.416 | 0 | 0.129 | -0.394 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income
| -14.02 | -13.925 | -17.203 | -17.655 | -16.748 | -19.355 | -21.267 | -21.765 | -19.374 | -24.613 | -21.482 | -19.701 | -16.251 | -23.181 | -16.667 | -20.772 | -14.819 | -11.51 | -8.118 |
| Net Income Ratio
| -6.195 | -5.908 | 0 | -6.084 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.22 | -0.24 | -0.62 | -0.64 | -0.61 | -0.7 | -0.78 | -0.79 | -0.71 | -0.9 | -0.78 | -0.98 | -0.61 | -0.87 | -0.63 | -0.78 | -0.56 | -28 | -19.85 |
| EPS Diluted
| -0.22 | -0.24 | -0.62 | -0.64 | -0.61 | -0.7 | -0.78 | -0.79 | -0.71 | -0.9 | -0.78 | -0.98 | -0.61 | -0.87 | -0.63 | -0.78 | -0.56 | -27.98 | -19.83 |
| EBITDA
| -14.422 | -14.229 | -16.096 | -17.106 | -16.901 | -19.624 | -23.027 | -22.678 | -19.733 | -24.107 | -20.784 | -19.162 | -15.579 | -22.634 | -16.17 | -20.254 | -14.307 | -11.233 | -7.987 |
| EBITDA Ratio
| -6.373 | -6.037 | 0 | -6.093 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |